Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTA 901 in Healthy Adults (SAD/MAD)
NCT02666963Phase 1Completed
- Sponsor
- Biogen
- Start
- Jan 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cemdomespib in diabetic neuropathy (4 arms), sponsored by Biogen. Primary endpoint: Safety and Tolerability Assessment at 14 days. Started Jan 2017; status: completed.
02
Drugs
cemdomespib
03
Conditions
diabetic neuropathy
Beyond the preview
Go deeper on NCT02666963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02666963.